Inactive Instrument

AgeX Therapeutics, Inc.

AGE

US00848H2076

AgeX Therapeutics, Inc. amended terms of the transaction

January 24, 2023

On January 25, 2023, the company has received its sixth and final tranche. The company has received $500,000 in the tranche.

Latest news about AgeX Therapeutics, Inc.

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	Mar. 25	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	Jan. 11	CI
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023	Dec. 01	CI
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	Nov. 17	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000	Nov. 14	MT
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	23-09-08	CI
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.	23-08-29	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000	23-08-14	MT
AgeX Therapeutics, Inc. Announces CEO Changes	23-08-14	CI
Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee	23-08-14	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation	23-07-25	MT
AgeX Therapeutics, Inc. announced that it has received $13.66 million in funding from Juvenescence Ltd.	23-06-06	CI
AgeX Therapeutics to Appeal NYSE American's Delisting Notice	23-05-23	MT
AgeX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q4 Revenue $8,000	23-03-31	MT
AgeX Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
AgeX Therapeutics, Inc. announced that it has received $10 million in funding from Juvenescence Ltd.	23-03-12	CI
AgeX Therapeutics, Inc. amended terms of the transaction	23-01-24	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Revenue $9,000	22-11-10	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Revenue $9,000	22-11-10	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Loss $-0.06	22-11-10	MT

AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The Company's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.

Sector

More about the company